GRAMD4 anticorps (full length)

N° du produit ABIN7878318

L’anticorps anti-GRAMD4 Monoclonal Souris est utilisé pour la détection de GRAMD4 dans des échantillons de Humain. Il a été validé pour FACS et IF.

Aperçu rapide pour GRAMD4 anticorps (full length) (ABIN7878318)

Antigène: GRAMD4 (GRAM Domain Containing 4 (GRAMD4))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp GRAMD4 est non-conjugé

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Classe de qualité: Carrier-free

Clone: PCRP-GRAMD4-1A10

Détail du produit anti-GRAMD4 anticorps

Épitope: full length

Fonction: GRAMD4 Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: Recombinant full-length human GRAMD4 protein was used as the immunogen for the GRAMD4 antibody.

Isotype: IgG1

Information d'application

Indications d'application: Optimal dilution of the GRAMD4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Aliquot the GRAMD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur GRAMD4

Antigène: GRAMD4 (GRAM Domain Containing 4 (GRAMD4))

Autre désignation: GRAMD4

Sujet: The gene encoding GRAMD4 (GRAM domain-containing protein 4) maps to human chromosome 22, which houses over 500 genes and is the second smallest human chromosome. GRAMD4, also designated death-inducing protein (DIP), is a 578 amino acid mitochondrial membrane protein that acts as an essential mediator of the p53-independent E2F-1 death pathway, which is frequently found to be deregulated in several types of cancers. Overexpression of GRAMD4 results in a strong apoptotic response involving caspase-3 activation and cleavage of poly(ADP-ribose)-polymerase. GRAMD4 is expressed in lung and in primary lung squamous cell carcinoma (LSCC) and shows upregulation in mitochondria by E2F1 after addition of 4-hydroxytamoxifen. This evidence suggests that GRAMD4 may be a potential target for cancer therapies.

UniProt: Q6IC98